Immunocore Holdings plc (NASDAQ:IMCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) has been given an average rating of "Moderate Buy" by the thirteen brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $65.64.

Several brokerages have weighed in on IMCR. HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research note on Wednesday, March 12th. Needham & Company LLC reiterated a "buy" rating and issued a $71.00 price target on shares of Immunocore in a research note on Wednesday, March 12th. Finally, Morgan Stanley restated an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a research note on Friday, March 7th.

Insider Buying and Selling at Immunocore

In other news, Director Bros. Advisors Lp Baker bought 807,338 shares of the stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the purchase, the director now directly owns 2,144,060 shares in the company, valued at $63,721,463.20. The trade was a 60.40 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 9.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunocore

Large investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new stake in shares of Immunocore in the fourth quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. increased its holdings in Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after acquiring an additional 960 shares in the last quarter. NEOS Investment Management LLC increased its holdings in Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after acquiring an additional 1,102 shares in the last quarter. Tema Etfs LLC acquired a new position in Immunocore during the fourth quarter worth $330,000. Finally, Virtus ETF Advisers LLC lifted its holdings in Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after purchasing an additional 3,238 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

Immunocore Stock Down 1.1 %

Shares of IMCR stock traded down $0.32 during mid-day trading on Friday, hitting $29.32. The stock had a trading volume of 165,909 shares, compared to its average volume of 273,286. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The firm's 50-day moving average is $29.98 and its two-hundred day moving average is $31.05. The firm has a market capitalization of $1.47 billion, a P/E ratio of -30.86 and a beta of 0.79. Immunocore has a 12-month low of $27.19 and a 12-month high of $66.00.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.